Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Comment] Prevention of fractures in patients with osteoporosis

Patients with osteoporosis who have previously had fragility fractures have the highest risk of recurrent fractures, and 10–20% of those with recent fractures will re-fracture within just 2 years.1 Yet most patients who have had fractures are untreated and those who are tend to be treated conservatively, namely with an oral bisphosphonate.2 Antiresorptive drugs, such as bisphosphonates and denosumab, and bone-forming agents, such as teriparatide, both increase bone mineral mass and reduce fragility fractures in patients with osteoporosis.